ABT-510 acetate

Research use only, not for human use.

ABT-510 acetate is an endogenous anti-angiogenic TSP peptide inhibitor, a thrombospondin analog, with anti-inflammatory, anti-cancer and anti-angiogenic activity that induces apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer.

ABT-510 acetate is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 acetate also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 acetate can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD).

Apoptosis Analysis Cell Line:ID8, SKOV3, OVCAR3, and CAOV3 cellsConcentration:1, 5, 10, 20, 50 nM Incubation Time:24 h Result:Induced ID8 cells apoptosis and increased in apoptosis in the human EOC cell lines SKOV3, OVCAR3, and CAOV3.Cell Proliferation Assay Cell Line:Tissue biopsies of B16F10 melanoma tumors grown in C57BL/6 mice Concentration:0-10 μM Incubation Time:7 days Result:Inhibited NO-stimulated vascular cell outgrowth into and invasion through extracellular matrix.

Animal Model:TSP-1-Null mice (C57BL/6 background; orthotopic, syngeneic model of epithelial ovarian cancer) Dosage:100 mg/kg Administration:Intraperitoneal injection; single daily for 90 daysResult:Reduced ovarian tumor growth in wild-type and TSP-1-Null Mice.Significantly reduced the volume of ascites and completely abolished the formation of peritoneal lesions.Reversed ovarian tumor hypervascularization and increased the proportion of mature blood vessels.Animal Model:TSP-1-Null mice (C57BL/6 background; 6-week-old; DSS-induced inflammatory bowel disease murine model) Dosage:60 mg/kg Administration:Subcutaneously implanted osmotic minipumps (0.5μL/h); single daily for 7 days Result:Significantly delayed DSS-induced bleeding and improved the overall severity of disease.Significantly diminished inflammation grading and angiogenesis.

——

Apoptosis

Apoptosis

Apoptosis

——

——

442526-87-6

1054.28

C48H87N13O13

>98% (HPLC)

In Vitro:?H2O : 100 mg/mL (94.85 mM; Ultrasonic)

C(C)(O)=O.C([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](NC([C@@H](NC(CNC(CN(C(C)=O)C)=O)=O)[C@H](C)C)=O)[C@H](CC)C)=O)[C@@H](C)O)=O)CCC)=O)[C@H](CC)C)=O)CCCNC(=N)N)(=O)N1[C@H](C(NCC)=O)CCC1

——

(-20℃)

With Ice Pack

≥ 2 years